医学
肺动脉高压
内皮
内皮功能障碍
胚胎血管重塑
肺动脉
内科学
肺
血栓
内皮干细胞
炎症
心脏病学
血管舒张
疾病
发病机制
心力衰竭
西地那非
一氧化氮
生物
体外
生物化学
作者
Kondababu Kurakula,Valérie F. E. D. Smolders,Olga Tura-Ceide,J. Wouter Jukema,Paul H.A. Quax,Marie‐José Goumans
出处
期刊:Biomedicines
[Multidisciplinary Digital Publishing Institute]
日期:2021-01-09
卷期号:9 (1): 57-57
被引量:148
标识
DOI:10.3390/biomedicines9010057
摘要
Pulmonary arterial hypertension (PAH) is a rare, complex, and progressive disease that is characterized by the abnormal remodeling of the pulmonary arteries that leads to right ventricular failure and death. Although our understanding of the causes for abnormal vascular remodeling in PAH is limited, accumulating evidence indicates that endothelial cell (EC) dysfunction is one of the first triggers initiating this process. EC dysfunction leads to the activation of several cellular signalling pathways in the endothelium, resulting in the uncontrolled proliferation of ECs, pulmonary artery smooth muscle cells, and fibroblasts, and eventually leads to vascular remodelling and the occlusion of the pulmonary blood vessels. Other factors that are related to EC dysfunction in PAH are an increase in endothelial to mesenchymal transition, inflammation, apoptosis, and thrombus formation. In this review, we outline the latest advances on the role of EC dysfunction in PAH and other forms of pulmonary hypertension. We also elaborate on the molecular signals that orchestrate EC dysfunction in PAH. Understanding the role and mechanisms of EC dysfunction will unravel the therapeutic potential of targeting this process in PAH.
科研通智能强力驱动
Strongly Powered by AbleSci AI